Ratings by Leerink (Andrew S. Berens)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 1/5/2026 | Incyte | INCY | Maintain | Outperform (N/A) |
|
Details | ||
| 12/8/2025 | Incyte | INCY | Maintain | Outperform (N/A) |
|
Details | ||
| 10/30/2024 | Incyte | INCY | Maintain | Outperform (N/A) |
|
Details | ||
| 12/13/2023 | Incyte | INCY | Upgrade | Outperform (Market Perform) |
61.86 (116.86) |
88.91% | Details | |
| 3/24/2023 | Incyte | INCY | Upgrade | Market Perform (Underperform) |
72.26 (116.86) |
61.72% | Details | |
| 2/6/2023 | Seagen | SGEN | Downgrade | Market Perform (Outperform) |
138.00 (228.74) |
65.75% | Details | |
| 9/13/2022 | Seagen | SGEN | Maintain | Outperform (N/A) |
|
Details | ||
| 7/19/2022 | Incyte | INCY | Maintain | Underperform (N/A) |
|
Details | ||
| 6/13/2022 | Turning Point Therapeutics Inc. | TPTX | Downgrade | Market Perform (Outperform) |
74.47 (76.01) |
2.07% | Details | |
| 5/11/2022 | Turning Point Therapeutics Inc. | TPTX | Maintain | Outperform (N/A) |
|
Details | ||
| 2/9/2022 | Incyte | INCY | Downgrade | Underperform (Market Perform) |
70.07 (116.86) |
66.78% | Details | |
| 9/23/2021 | Incyte | INCY | Upgrade | Market Perform (Underperform) |
69.59 (116.86) |
67.93% | Details | |
| 2/10/2021 | Incyte | INCY | Downgrade | Underperform (Market Perform) |
89.46 (116.86) |
30.63% | Details | |
| 1/12/2021 | Incyte | INCY | Maintain | Market Perform (N/A) |
|
Details | ||
| 12/14/2020 | Turning Point Therapeutics Inc. | TPTX | Maintain | Outperform (N/A) |
|
Details | ||
| 9/22/2020 | Seattle Genetics | SGEN | Maintain | Outperform (N/A) |
|
Details | ||
| 9/15/2020 | Seattle Genetics | SGEN | Maintain | Outperform (N/A) |
|
Details | ||
| 8/19/2020 | Turning Point Therapeutics Inc. | TPTX | Maintain | Outperform (N/A) |
|
Details | ||
| 7/31/2020 | Seattle Genetics | SGEN | Maintain | Outperform (N/A) |
|
Details | ||
| 7/7/2020 | Turning Point Therapeutics Inc. | TPTX | Maintain | Market Perform (N/A) |
|
Details | ||
| 4/20/2020 | Seattle Genetics | SGEN | Maintain | Outperform (N/A) |
|
Details | ||
| 2/11/2020 | Seattle Genetics | SGEN | Maintain | Outperform (N/A) |
|
Details | ||
| 1/28/2020 | Incyte | INCY | Maintain | Market Perform (N/A) |
|
Details |
